ESMO 2024: Tecentriq/Avastin's prospects as the first HCC adjuvant therapy fade
At ESMO Congress 2024, updated Phase III IMbrave050 trial data showed no significant RFS benefit for Tecentriq + Avastin as adjuvant therapy in high-risk HCC, despite earlier interim analysis benefits. Ongoing trials like CheckMate 9DX and KEYNOTE-93 aim to evaluate monotherapy options for HCC, with potential market impacts by 2030.
Reference News
The Phase III APOLLO trial presented at ESMO 2024 showed Chia Tai Tianqing's Focus V (anlotinib) plus Akeso's penpulimab significantly improved progression-free survival (PFS) and overall survival (OS) in first-line advanced hepatocellular carcinoma (aHCC) compared to sorafenib, with a manageable safety profile. This contrasts with the failure of Merck's Keytruda in the LEAP-002 trial. Elevar Therapeutic's PD-1 IO camrelizumab and TKI rivoceranib also showed benefits in the CARES-310 trial but with more adverse events. Despite these results, Roche's Tecentriq with bevacizumab remains the first-line standard of care in aHCC, predicted to generate $980m in sales by 2029.
At ESMO Congress 2024, updated Phase III IMbrave050 trial data showed no significant RFS benefit for Tecentriq + Avastin as adjuvant therapy in high-risk HCC, despite earlier interim analysis benefits. Ongoing trials like CheckMate 9DX and KEYNOTE-93 aim to evaluate monotherapy options for HCC, with potential market impacts by 2030.